University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 3L-12-3


A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with or without Chronic Viral Hepatitis.

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Immunotherapy
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anthony El-Khoueiry, M.D.
Other Trial Staff:  Ramona Lujan, R.N., Taison Tran, D.M., Arthur Alvarez, D.M., Arthur Alvarez, D.M., Catherine Ticong, R.N.

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.